AGBL2 and rheumatoid arthritis: Most PR patients tested positive for the commercial CCP2 test, and revealed an ACPA repertoire closer to that seen in the preclinical phase of RA [9] or in unaffected relatives of RA patients than in patients with RA [12, 19, 20].